Article

ABTB2 regulatory variant as predictor of epirubicin-based neoadjuvant chemotherapy in luminal A breast cancer

2020-05-22

Abstract excerpt

<h4>Background: </h4> Epirubicin combined with docetaxel is the cornerstone of neoadjuvant chemotherapy(NAC) for breast cancer. The efficacy of NAC for luminal A breast cancer patients is very limited, and single nucleotide polymorphism is one of the most important factor that influence the efficacy. Our study aimed to explore genetic markers for the efficacy of epirubicin combined with docetaxel for NAC in patien...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 61cb6650-e0c5-5b5d-85b6-6330e6e78be2
DOI: 10.21203/rs.3.rs-30033/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

ABTB2 regulatory variant as predictor of epirubicin-based neoadjuvant chemotherapy in luminal A breast cancerDOI 10.21203/rs.3.rs-30033/v1Read

Genomic and transcriptomic analysis of breast cancer identifies novel signatures associated with response to neoadjuvant chemotherapySemantic proximity Read

Effects of FGFR gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-docetaxel-based chemotherapy in breast cancer patientsSemantic proximity Read

Identification of DDIT4 as a Potential Prognostic Marker Associated with Chemotherapy and Immunotherapy Response in Triple-Negative Breast CancerSemantic proximity Read

The effect of DDIT3 on luminal A type breast cancerSemantic proximity Read

ADRB2 is a potential protective gene in breast cancer by regulating tumor immune microenvironmentSemantic proximity Read

Genome-wide association study of genetic variants related to anthracycline-induced cardiotoxicity in early breast cancer.Semantic proximity Read

Resistance to paclitaxel is associated with a variant of the gene BCL2 in multiple tumor typesSemantic proximity Read

A three lncRNA set: AC009975.1, POTEH-AS1 and AL390243.1 as nodal efficacy biomarker of neoadjuvant therapy for HER-2 positive breast cancerSemantic proximity Read

Differential Gene -Based Predictors of Neoadjuvant Chemotherapy Efficacy in Breast CancerSemantic proximity Read

Toxicity and Pharmacogenomic Biomarkers in Breast Cancer ChemotherapySemantic proximity Read

Genetic evaluation of BRCA1 associated a complex genes with triple-negative breast cancer susceptibility in Chinese women.Semantic proximity Read

Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents.Semantic proximity Read